Report
EUR 14.00 For Business Accounts Only

NIPRO increases its risk exposure and slightly lowers to Neutral

NIPRO (JP), a company active in the Medical Equipment industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date March 4, 2022, the closing price was JPY 1,052.00 and its expected value was estimated at JPY 1,084.84.
Underlying
Nipro Corporation

Nipro and its affiliates are mainly engaged in the manufacture and sale of medical products and glass products. Co. operates in four business segments: medical-related, pharmaceutical-related, pharma packaging and others. Co.'s principal products include injection and infusion-related products, artificial organ-related products, highly functional products, dialysis-related products and diabetic-related products; injectable drug and oral drugs; and glass for glass tube, ampoule, syrings and cartridges. In addition, Co. is engaged in the manufacture and sale of medical products manufacturing machines, the real estate leasing and the non-life insurance agency business.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch